ATE163231T1 - Kinaserezeptoraktivierungstest - Google Patents

Kinaserezeptoraktivierungstest

Info

Publication number
ATE163231T1
ATE163231T1 AT95903133T AT95903133T ATE163231T1 AT E163231 T1 ATE163231 T1 AT E163231T1 AT 95903133 T AT95903133 T AT 95903133T AT 95903133 T AT95903133 T AT 95903133T AT E163231 T1 ATE163231 T1 AT E163231T1
Authority
AT
Austria
Prior art keywords
receptor
cells
construct
tyrosine kinase
pct
Prior art date
Application number
AT95903133T
Other languages
English (en)
Inventor
Paul J Godowski
Melanie R Mark
Michael Daniel Sadick
Wai Lee Tan Wong
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/170,558 external-priority patent/US6001621A/en
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of ATE163231T1 publication Critical patent/ATE163231T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
AT95903133T 1993-11-23 1994-11-18 Kinaserezeptoraktivierungstest ATE163231T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15756393A 1993-11-23 1993-11-23
US08/170,558 US6001621A (en) 1993-11-23 1993-12-20 Protein tyrosine kinases
US28630594A 1994-08-05 1994-08-05

Publications (1)

Publication Number Publication Date
ATE163231T1 true ATE163231T1 (de) 1998-02-15

Family

ID=27388031

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95903133T ATE163231T1 (de) 1993-11-23 1994-11-18 Kinaserezeptoraktivierungstest

Country Status (12)

Country Link
US (3) US6025145A (de)
EP (1) EP0730740B1 (de)
JP (1) JP3442784B2 (de)
AT (1) ATE163231T1 (de)
AU (1) AU698975B2 (de)
CA (1) CA2175892C (de)
DE (1) DE69408541T2 (de)
DK (1) DK0730740T3 (de)
ES (1) ES2116066T3 (de)
GR (1) GR3026430T3 (de)
HK (1) HK1008440A1 (de)
WO (1) WO1995014930A1 (de)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0711341A4 (de) * 1993-07-29 2001-12-19 Cor Therapeutics Inc Rezeptorfunktionstests
US6287784B1 (en) * 1993-11-23 2001-09-11 Genentech, Inc. Kinase receptor activation assay
EP1619250B1 (de) 1996-01-08 2009-11-25 Genentech, Inc. OB Rezeptor-Variante und Liganden
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20050019325A1 (en) 1996-01-08 2005-01-27 Carter Paul J. WSX receptor agonist antibodies
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
AU727606B2 (en) 1996-07-12 2000-12-14 Genentech Inc. Gamma-heregulin
NZ333325A (en) 1996-07-12 2000-06-23 Genentech Inc Recombinant chimeric heteromultimer adhesins comprising extracellular domains of ErbB receptors
US6433154B1 (en) * 1997-06-12 2002-08-13 Bristol-Myers Squibb Company Functional receptor/kinase chimera in yeast cells
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
FR2776661B1 (fr) * 1998-03-26 2002-04-05 Centre Nat Rech Scient Polypeptide immunoreactif du recepteur trka du ngf et utilisations
US6253441B1 (en) * 1999-04-16 2001-07-03 General Electric Company Fabrication of articles having a coating deposited through a mask
GB9918057D0 (en) * 1999-07-30 1999-10-06 Univ Bristol Therapeutic agents
EP1229919A2 (de) * 1999-08-06 2002-08-14 Institut Pasteur Verfahren zum beeinflussen der phosphorylierung von eukaryotischen zellen unter verwendung von thiamintriphosphat
US6406869B1 (en) 1999-10-22 2002-06-18 Pharmacopeia, Inc. Fluorescent capture assay for kinase activity employing anti-phosphotyrosine antibodies as capture and detection agents
AU7142201A (en) * 2000-06-22 2002-01-02 Genentech Inc Agonist anti-trk-c monoclonal antibodies
US7087726B2 (en) 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1436598B1 (de) 2001-09-10 2013-11-27 Meso Scale Technologies LLC Assay-puffer, diesen enthaltende zusammensetzungen sowie diesen verwendende verfahren
AU2003228225B2 (en) * 2002-03-01 2010-05-13 Roger Williams Hospital SHC protein-related methods and compositions for the prognosis of breast, prostate and ovarian cancer
US20050004008A1 (en) * 2002-03-01 2005-01-06 Frackelton A. Raymond SHC proteins as therapeutic targets in proliferative diseases
MXPA05000403A (es) 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
CA2500901A1 (en) * 2002-10-04 2004-04-22 Rinat Neuroscience Corp. Methods for treating cardiac arrhythmia and preventing death due to cardiac arrhythmia using ngf antagonists
MXPA05003502A (es) * 2002-10-08 2005-09-30 Rinat Neuroscience Corp Metodo para tratar dolor post-quirurgico al administrar un antagonista del factor de crecimiento de nervios y composiciones que contienen el mismo.
AU2003304238A1 (en) * 2002-10-08 2005-01-13 Rinat Neuroscience Corp. Methods for treating post-surgical pain by administering an anti-nerve growth factor antagonist antibody and compositions containing the same
UA80447C2 (en) 2002-10-08 2007-09-25 Methods for treating pain by administering nerve growth factor antagonist and opioid analgesic
CA2511295A1 (en) * 2002-12-23 2004-07-15 Rinat Neuroscience Corp. Methods for treating taxol-induced sensory neuropathy
US9498530B2 (en) 2002-12-24 2016-11-22 Rinat Neuroscience Corp. Methods for treating osteoarthritis pain by administering a nerve growth factor antagonist and compositions containing the same
NZ540730A (en) * 2002-12-24 2010-09-30 Rinat Neuroscience Corp Anti-NGF antibodies and methods using same
US7569364B2 (en) 2002-12-24 2009-08-04 Pfizer Inc. Anti-NGF antibodies and methods using same
ATE491444T1 (de) * 2003-02-19 2011-01-15 Rinat Neuroscience Corp Verfahren zur behandlung von schmerzen durch verabreichung eines nervenwachstumsfaktor- antagonisten und eines nsaid und diese enthaltende zusammensetzung
ES2263862T3 (es) * 2003-03-07 2006-12-16 Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Ensayo de quinasa de linfoma anaplasico, sus reactivos y composiciones.
RS54160B1 (sr) 2003-03-19 2015-12-31 Biogen Idec Ma Inc. Protein koji se vezuje za nogo receptor
EP1620127A4 (de) * 2003-03-20 2007-04-04 Rinat Neuroscience Corp Verfahren zur behandlung von taxol-induzierten darmstörungen
US7579157B2 (en) * 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
US20050124965A1 (en) * 2003-12-08 2005-06-09 Becton, Dickinson And Company Phosphatase inhibitor sample collection system
KR101504729B1 (ko) 2004-04-07 2015-03-19 리나트 뉴로사이언스 코프. 신경성장인자 길항제의 투여에 의한 골암 통증 치료용 약학적 조성물
SV2006002143A (es) 2004-06-16 2006-01-26 Genentech Inc Uso de un anticuerpo para el tratamiento del cancer resistente al platino
CA2572193A1 (en) 2004-06-24 2006-01-05 Biogen Idec Ma Inc. Treatment of conditions involving oligodendrocytes with sp35 based agents
US7560111B2 (en) 2004-07-22 2009-07-14 Genentech, Inc. HER2 antibody composition
US7597884B2 (en) 2004-08-09 2009-10-06 Alios Biopharma, Inc. Hyperglycosylated polypeptide variants and methods of use
EP1662258A1 (de) * 2004-11-25 2006-05-31 Sirenade Pharmaceuticals AG In Vitro Testverfahren zum Nachweis von substratfreier Proteinkinase-Aktivität
US7449184B2 (en) 2005-01-21 2008-11-11 Genentech, Inc. Fixed dosing of HER antibodies
PT1850874E (pt) 2005-02-23 2013-12-02 Genentech Inc Extensão de tempo até a progressão da doença ou sobrevivência em pacientes com cancro de ovário usando pertuzumab
US7189522B2 (en) 2005-03-11 2007-03-13 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
WO2006098804A2 (en) * 2005-03-11 2006-09-21 Chembio Diagnostic Systems, Inc. Dual path immunoassay device
AR054260A1 (es) * 2005-04-26 2007-06-13 Rinat Neuroscience Corp Metodos de tratamiento de enfermedades de la neurona motora inferior y composiciones utilizadas en los mismos
EP2238986A3 (de) 2005-07-08 2010-11-03 Biogen Idec MA Inc. Sp35-Antikörper und Verwendungen dafür
WO2007058965A1 (en) * 2005-11-11 2007-05-24 Roger Williams Hospital P66-shc as predictive marker in cancer treatment
NZ598421A (en) 2005-12-02 2013-11-29 Biogen Idec Inc Treatment of Conditions Involving Demyelination
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
US8128926B2 (en) 2007-01-09 2012-03-06 Biogen Idec Ma Inc. Sp35 antibodies and uses thereof
CN101980603A (zh) * 2007-10-11 2011-02-23 比奥根艾迪克Ma公司 LINGO-1和TrkB拮抗剂的用途
ATE539165T1 (de) 2007-10-19 2012-01-15 Becton Dickinson Co Verfahren zum nachweis von beta-lactamase
CA2971968C (en) * 2007-10-24 2019-08-13 Biomarker Strategies, Llc Improved methods and devices for cellular analysis
ATE545023T1 (de) 2007-10-29 2012-02-15 Eisai R&D Man Co Ltd Verfahren zur vorhersage der fähigkeit einer zearalenon-analogverbindung für die krebsbehandlung
CN101918540B (zh) * 2007-11-08 2016-05-11 比奥根Ma公司 Lingo-4拮抗剂在治疗涉及脱髓鞘的疾患中的应用
WO2009077993A2 (en) 2007-12-17 2009-06-25 Pfizer Limited Treatment of interstitial cystitis
JP5608100B2 (ja) 2008-02-08 2014-10-15 メディミューン，エルエルシー 低下したＦｃリガンド親和性を有する抗ＩＦＮＡＲ１抗体
WO2009150623A1 (en) 2008-06-13 2009-12-17 Pfizer Inc Treatment of chronic prostatitis
AU2009269099B2 (en) 2008-07-09 2016-03-10 Biogen Ma Inc. Compositions comprising antibodies to LINGO or fragments thereof
US20100022916A1 (en) 2008-07-24 2010-01-28 Javanbakhsh Esfandiari Method and Apparatus for Collecting and Preparing Biological Samples for Testing
JP5739807B2 (ja) * 2008-08-18 2015-06-24 ディスカヴァーエックス コーポレイション 受容体チロシンキナーゼアッセイ
CN102159204B (zh) 2008-09-19 2015-04-01 辉瑞公司 稳定的液体抗体制剂
WO2010047778A1 (en) 2008-10-20 2010-04-29 Becton Dickinson And Company Compositions for the detection of intracellular bacterial targets and other intracellular microorganism targets
WO2010146511A1 (en) 2009-06-17 2010-12-23 Pfizer Limited Treatment of overactive bladder
BR112012009828B8 (pt) 2009-10-26 2022-10-25 Hoffmann La Roche Método para a produção de uma imunoglobulina glicosilada e seu uso
US8603835B2 (en) 2011-02-10 2013-12-10 Chembio Diagnostic Systems, Inc. Reduced step dual path immunoassay device and method
WO2013101771A2 (en) 2011-12-30 2013-07-04 Genentech, Inc. Compositions and method for treating autoimmune diseases
JP2015518829A (ja) 2012-05-14 2015-07-06 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． 運動ニューロンに関する状態の処置のためのｌｉｎｇｏ−２アンタゴニスト
WO2015050959A1 (en) 2013-10-01 2015-04-09 Yale University Anti-kit antibodies and methods of use thereof
AU2015240088B2 (en) * 2014-03-31 2021-07-22 Merck Patent Gmbh Method for detecting protein modifications using specific antibodies
MX2016012881A (es) 2014-04-02 2017-05-10 Chembio Diagnostic Systems Inc Inmunoensayo que utiliza un conjugado de captura.
US20160116466A1 (en) 2014-10-27 2016-04-28 Chembio Diagnostic Systems, Inc. Rapid Screening Assay for Qualitative Detection of Multiple Febrile Illnesses
CA2973266A1 (en) 2015-01-08 2016-07-14 Biogen Ma Inc. Lingo-1 antagonists and uses for treatment of demyelinating disorders
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3311889A1 (de) * 1983-03-31 1984-10-11 Byk-Mallinckrodt Chemische Produkte Gmbh, 6057 Dietzenbach Verfahren zur irreversiblen bindung von protein an polystyroloberflaechen unter erhaltung der biologischen aktivitaet, so erhaltene polystyroloberflaechen und ihre verwendung
US4859609A (en) * 1986-04-30 1989-08-22 Genentech, Inc. Novel receptors for efficient determination of ligands and their antagonists or agonists
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
US5336603A (en) * 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
WO1993015201A1 (en) * 1992-01-22 1993-08-05 New England Deaconess Hospital Novel protein tyrosine kinases
WO1993021230A1 (en) * 1992-04-10 1993-10-28 Dana-Farber Cancer Institute, Inc. Activation-state-specific phosphoprotein immunodetection
AU6117294A (en) * 1993-02-16 1994-09-14 Auckland Uniservices Limited Developmental tyrosine kinases and their ligands

Also Published As

Publication number Publication date
HK1008440A1 (en) 1999-05-07
EP0730740A1 (de) 1996-09-11
US6025145A (en) 2000-02-15
DK0730740T3 (da) 1998-09-28
EP0730740B1 (de) 1998-02-11
CA2175892C (en) 2000-03-07
JP3442784B2 (ja) 2003-09-02
ES2116066T3 (es) 1998-07-01
DE69408541D1 (de) 1998-03-19
AU698975B2 (en) 1998-11-12
JPH09505889A (ja) 1997-06-10
GR3026430T3 (en) 1998-06-30
US5891650A (en) 1999-04-06
DE69408541T2 (de) 1998-08-06
US5914237A (en) 1999-06-22
AU1210895A (en) 1995-06-13
CA2175892A1 (en) 1995-06-01
WO1995014930A1 (en) 1995-06-01

Similar Documents

Publication Publication Date Title
ATE163231T1 (de) Kinaserezeptoraktivierungstest
Wilce et al. Physicochemical basis of amino acid hydrophobicity scales: evaluation of four new scales of amino acid hydrophobicity coefficients derived from RP-HPLC of peptides
CN1703624B (zh) 用于检测mhc-ⅰ类和mhc-ⅱ类结合肽的方法和体系
ATE217344T1 (de) Antigen bindende peptide (abtides) aus peptidbibliotheken
DE69334100D1 (de) Elk ligand, ein cytokin
Kowalczyńska et al. Fibronectin adsorption and arrangement on copolymer surfaces and their significance in cell adhesion
TR200002257T2 (tr) Nükleer reseptör ligandları ve ligand bağlanma domainleri.
EP0873998A3 (de) Rezeptor-Protein und seine Verwendung
US4703016A (en) Silver stain for rapid, quantitative detection of polypeptides and nucleic acids
CA2279881A1 (en) A method of identifying modulators of cell surface membrane receptors useful in the treatment of disease
MERCIER et al. Structure primaire du caséinomacropeptide de la caséine κB1 bovine
Ihara et al. [3H] BQ-123, a highly specific and reversible radioligand for the endothelin ETA receptor subtype
DE59914768D1 (de) Entstörung von Immunoassays durch Substanzen, die aus den Framework-Regionen von Antikörpern abgeleitet sind
CA2203246A1 (en) Alk-7 (activin like kinase), a serine threonine kinase receptor
CN101896816A (zh) 用于检测分析物的方法
Chin et al. The use of tributylphosphine and 4-(aminosulfonyl)-7-fluoro-2, 1, 3-benzoxadiazole in the study of protein sulfhydryls and disulfides
Rehfeld et al. Residue-specific radioimmunoanalysis: a novel analytical tool. Application to the C-terminus of CCK/gastrin peptides
Proniewicz et al. Role of Phe‐D5 isotopically labeled analogues of bradykinin on elucidation of its adsorption mode on Ag, Au, and Cu electrodes. Surface‐enhanced Raman spectroscopy studies
Moss et al. Solubility and posttranslational regulation of GP130/F11--a neuronal GPI-linked cell adhesion molecule enriched in the neuronal membrane skeleton.
Bähr et al. Interaction of the effector domain of MARCKS and MARCKS-related protein with lipid membranes revealed by electric potential measurements
CA2294969A1 (en) Surfaces coated with streptavindin/avidin
WO2003000732A3 (en) Fragments of the retinoic acid-related orphan receptor (ror) comprising the lig and binding domain (lbd), crystal structure of the lbd of ror-beta and their applications
Dybkaer Quantities and units for biological reference materials used with in vitro diagnostic measuring systems for antibodies
JP2000214165A5 (de)
AU8857991A (en) Polypeptides having human dopaminergic receptor activity, nucleic acids coding for said polypeptides and uses thereof for screening active substances on said polypeptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification